(lp0
S'Maxim Analyst Comments on Cytori Therapeutics Inc Following Azaya Acquisition Smarter Analyst - Jan 19, 2017 Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Cytori Therapeutics Inc  with a price target of $6.00, after the drug developer announced the acquisitions of Azaya Therapeutics for its proprietary liposomal nanoparticle&nbsp;...Cytori Therapeutics stock surges 7.9% on agreement to buy assets from Azaya ... - MarketWatchCytori Therapeutics  to Acquire Assets from Privately Held Azaya ... - StreetInsider.com'
p1
aS'Cytori Therapeutics Inc  Downgraded to Sell at Zacks Investment Research Sports Perspectives - 6 hours ago Cytori Therapeutics logo Cytori Therapeutics Inc  was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued on Monday.Zacks Investment Research downgraded Cytori Therapeutics Inc  to ... - Breaking Finance News'
p2
aS'Traders Take Note: Cytori Therapeutics Inc  Stock Drops, Weakness ... CML News - 14 hours ago Take Note: Cytori Therapeutics Inc  has hit some technical weakness in its momentum, and while it has not broken down all the way through support -- watch the key levels that we discuss below and further, watch the stochastics and&nbsp;...'
p3
aS'Correcting The Facts On Cytori Therapeutics Seeking Alpha - Apr 14, 2015 On April 8th, 2015, TheStreet.com published an article by Adam Feuerstein on Cytori Therapeutics . The article was notable for its vindictiveness as it skewered the company for a Benzinga article that included an interview with Cytori CEO,&nbsp;...'
p4
aS'Stock Update : Cytori Therapeutics Inc Announces Increase of ... Smarter Analyst - Sep 19, 2016 Cytori Therapeutics Inc  announced that the Company and Biomedical Advanced Research and Development Authority , a division of the U.S.'
p5
aS'Stock Update : Cytori Therapeutics Inc Partner Kerastem Completes ... Smarter Analyst - Sep 26, 2016 Cytori Therapeutics Inc  announced that its licensee Kerastem Technologies, LLC, has completed enrollment of STYLE, a US phase II clinical trial investigating early stage female and male pattern hair loss.'
p6
aS"Cytori Therapeutics'  CEO Marc Hedrick on Q1 2016 Results - Earnings ... Seeking Alpha - May 11, 2016 Second, management feels that the combination of the forecasted spend and revenue may be sufficient to get the Company to the point of breakeven by 2018.Stock Update : Cytori Therapeutics Inc Granted Broad European ... - Smarter Analyst"
p7
aS'Cytori Therapeutics Inc.: Cytori Completes Acquisition of Azaya Therapeutics ... The Wall Street Transcript - Feb 15, 2017 15, 2017  -- Cytori Therapeutics, Inc.  today announced it has completed its acquisition of assets of privately held Azaya Therapeutics, Inc., a leader in the research, development and manufacturing of nanoparticle&nbsp;...Cytori Therapeutics, Inc.  PT Raised to $10 at Maxim Group on Closure of ... - StreetInsider.comCytori Therapeutics  Stock: Gaining On Price Target Increase - CNA Finance '
p8
aS"Cytori Therapeutics'  CEO Marc Hedrick on Q2 2016 Results - Earnings ... Seeking Alpha - Aug 5, 2016 Good afternoon, ladies and gentlemen. Welcome to Cytori Therapeutics Second Quarter 2016 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be open for your questions following the presentation."
p9
aS"Maxim's Biotech Insights: Cytori Therapeutics Inc , StemCells Inc  Smarter Analyst - Mar 28, 2016 Recent developments in biotech stocks Cytori Therapeutics Inc  and StemCells Inc  attract analysts' attention as pipeline treatments inch toward the end of their final testing phases."
p10
a.